ESMO Congress | Conference

Niraparib Highly Effective as Maintenance Therapy for Recurrent Ovarian Cancer

October 8th 2016

Maintenance therapy with niraparib reduced the risk of progression or death by 73% compared with placebo for patients with germline BRCA-positive platinum-sensitive, recurrent ovarian cancer.

Adjuvant Ipilimumab Improves Survival in High-Risk Melanoma

October 8th 2016

Treatment with ipilimumab reduced the risk of death by 28% versus placebo in patients with high-risk stage III melanoma.

Dr. Llombart-Cussac on the CASCADE Study in Metastatic Breast Cancer

October 8th 2016

Antonio Llombart-Cussac, MD, PhD, medical oncologist, chairman, Medical Oncology Service, University Hospital Arnau de Vilanova in Valencia, Spain, discusses the CASCADE study, which assessed declines in treatment efficacy over time in patients with metastatic breast cancer, during an interview at the 2016 ESMO Congress.

Dr. Bastholt on Lenvatinib in NSCLC

October 8th 2016

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses the use of lenvatinib to treat patients with non-small cell lung cancer at the 2016 ESMO Congress.

High Response Rates With Rucaparib in Heavily Pretreated Ovarian Cancer

October 7th 2016

The majority of heavily pretreated patients with high-grade ovarian cancer and germline or somatic BRCA mutations showed a durable response to rucaparib.

Neoadjuvant Anti-PD-1 Therapy Active in NSCLC

October 7th 2016

Almost 40% of patients with resected early-stage non–small cell lung cancer had evidence of tumor regression following neoadjuvant treatment with nivolumab (Opdivo) in a preliminary clinical trial.

Thousands of Melanoma Patients in Europe Not Receiving Novel Agents

October 7th 2016

Over one-fourth of patients with metastatic melanoma in Europe do not have access to groundbreaking therapies that could extend their lives.

Dr. Felip Discusses Ceritinib's Response in ALK+ NSCLC

November 12th 2014

Enriqueta Felip, MD, PhD, medical oncologist, Vall d'Hebron University Hospital, Barcelona, Spain, discusses the efficacy and safety of ceritinib in patients with ALK-positive non-small cell lung cancer (NSCLC).

Targeting Src Adds No Benefit in VEGF-Resistant Metastatic Renal Cell Carcinoma

October 6th 2014

Adding saracatinib to vascular endothelial growth factor (VEGF)-targeted therapy did not improve response rates or overall survival while adding to toxicity in VEGF-resistant metastatic renal cell carcinoma

Dr. Rolfo Discusses the Potential Utility of Ceritinib

October 2nd 2014

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

Dr. Herbst on the Next Generation of Lung Cancer Trials

October 1st 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

Dr. Ledermann Discusses Olaparib in Ovarian Cancer

October 1st 2014

Jonathan Ledermann, BSc, MD, FRCP, Professor of Medical Oncology in the UCL Cancer Institute, University College London, discusses health-related quality of life during olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation.

Dr. Saab on a Phase II Study of the Oncolytic Virus Reolysin for Pancreatic Cancer

September 30th 2014

Tanios Bekaii-Saab, MD, discusses the results of a phase II study of the oncolytic virus reolysin in the first-line treatment metastatic adenocarcinoma of the pancreas.

Durable Responses Observed with Nivolumab in Previously Treated mRCC

September 30th 2014

Durable responses were obtained with the immune checkpoint inhibitor nivolumab, with a manageable safety profile, in a phase II dose-ranging trial conducted in patients with previously treated metastatic renal cell carcinoma (mRCC).

New Data Provide Insight Into Optimal Pre-Chemo Treatments for mCRPC

September 30th 2014

The combination of abiraterone acetate and prednisone has demonstrated a statistically significant improvement in overall survival (OS) for men with metastatic castration-resistant prostate cancer (mCRPC) who had not received prior treatment with chemotherapy

Dabrafenib/Trametinib Combo Improves Survival Over Vemurafenib in Phase III COMBI-v Trial

September 30th 2014

Patients with unresectable melanoma had a significant improvement in the odds of survival when treated in first line with a combination of BRAF and MEK inhibitors, as opposed to anti-BRAF monotherapy

Expanded 80405 Study Mutation Analysis Fails to Resolve Targeted Therapy Quandary in mCRC

September 30th 2014

All patients with metastatic colorectal cancer should undergo RAS mutation testing to ensure optimal patient selection for EGFR inhibitor therapy.

Dr. Motzer on a Phase II Trial of Nivolumab for mRCC

September 30th 2014

Robert J. Motzer, MD, attending physician, Memorial Sloan Kettering Cancer Center, provides an overview of a phase II study of nivolumab for the treatment of patients with clear cell metastatic renal cell carcinoma.

Combination BRAF, MEK Inhibition "New Standard" for Previously Untreated BRAF-Mutant Melanoma

September 29th 2014

Inhibiting BRAF and MEK at the same time improves progression-free survival (PFS) more so than BRAF inhibition alone in patients with BRAF V600 mutation-positive metastatic melanoma, according to results of a phase III placebo-controlled trial.

Pembrolizumab Shows Promise in Advanced Gastric Cancer

September 29th 2014

In patients with advanced gastric cancer expressing PD-L1, pembrolizumab (Keytruda) has robust antitumor activity and an acceptable safety profile